← Back to Search

Monoclonal Antibodies

PF-07820435 + Sasanlimab for Cancer

Phase 1

Waitlist Available

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through up to 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to test the safety and effectiveness of PF-07820435 alone or in combination with sasanlimab in patients with advanced or metastatic solid tumors. The first part of the study

Who is the study for?

This trial is for adults with certain advanced cancers (like lung, kidney, colorectal) who've tried standard treatments without success or can't tolerate them. They need at least one measurable tumor and must provide tissue samples. It's not open to those who haven't had specific prior therapies if available and tolerable.

What is being tested?

The study tests PF-07820435 alone and with Sasanlimab in patients with advanced solid tumors. Part 1 finds the best dose; Part 2 uses this dose to see how well it works in different cancer types.

What are the potential side effects?

While the side effects aren't listed here, similar cancer drugs often cause fatigue, nausea, skin reactions, immune-related issues like inflammation of organs, and increased infection risk.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of patients with adverse events (AEs)

Number of patients with clinically significant lab abnormalities

Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B)

+1 more

Secondary study objectives

AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2

AUClast (area under the curve from time 0 to the last measurable timepoint) of PF-07820435 and its active metabolite

Change from baseline of immune markers within biopsied tumor tissue

+10 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups

Experimental Treatment

Group I: Monotherapy dose escalation (Part 1A)Experimental Treatment1 Intervention

Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles

Group II: Expansion (Part 2) - Tumor specific Arm BExperimental Treatment2 Interventions

Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles

Group III: Expansion (Part 2) - Tumor specific Arm AExperimental Treatment2 Interventions

Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles

Group IV: Expansion (Part 2) - Arm CExperimental Treatment1 Intervention

Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles

Group V: Combination dose escalation (Part 1B)Experimental Treatment2 Interventions

Participants will receive PF-07820435 orally at the prescribed dose and frequency, in combination with sasanlimab (subcutaneous injection) at a fixed dose once every 4 weeks in 28-day cycles

Do I qualify?Apply below to find out